Hem

Press release from Companies

Publicerat: 2020-11-30 09:00:00

DanCann Pharma A/S: The Interim Report 3rd Quarter 2020 for DanCann Pharma A/S is hereby enclosed

CEO of DanCann Pharma A/S, Mr. Jeppe Krog Rasmussen, states:
 
"Overall, this Q3 2020 report reflect the ongoing development phase that the company is undergoing. This interim report is also our first opportunity to send our gratitude to all of you who have chosen to follow our journey and participate in the IPO. We have an exciting future ahead of us and we are now a few steps closer to realizing our vision.

The period for Q3 2020 largely reflects the large and (time) demanding work leading up to our IPO – which we completed with great success where our IPO was subscribed to approx. 183 percent (DKK 55 million) – and approx. 433 percent for the publicly part (non-pre-subscribed).

We are still overwhelmed and incredibly grateful for the great interest shown in our new share issue. The proceeds we have received will be used solely to develop our ability to make a difference for those in need for alternative treatment. I would like to welcome our many new shareholders (1,644 new shareholders from the day we were listed) who have become a part of our company and journey. Thank you to all parties who have somehow been involved and made all this possible."

The report can be found on the following page.

 

About DanCann Pharma
 

 DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
 

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Email: jkr@dancann.com
Website: www.dancann.com

Läs mer hos Cision
Läs mer om DanCann Pharma A/S

Prenumeration